William Blair Downgrades Tempus AI (NASDAQ:TEM) to Market Perform

Tempus AI (NASDAQ:TEM) was downgraded by stock analysts at William Blair from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Wednesday, MarketBeat.com reports.

Other equities analysts also recently issued reports about the stock. Piper Sandler reiterated a “neutral” rating and issued a $70.00 target price (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $56.00 price objective on shares of Tempus AI in a research report on Tuesday, January 14th. Bank of America increased their target price on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research report on Friday, December 13th. Guggenheim initiated coverage on shares of Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 price target on the stock. Finally, Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and increased their price objective for the company from $45.00 to $65.00 in a report on Monday, November 11th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $58.55.

Tempus AI Price Performance

TEM opened at $83.75 on Wednesday. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI has a 12 month low of $22.89 and a 12 month high of $86.00. The stock has a fifty day moving average price of $45.82 and a 200-day moving average price of $49.97.

Insider Activity at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 51,504 shares of Tempus AI stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the completion of the sale, the executive vice president now directly owns 246,085 shares in the company, valued at approximately $10,431,543.15. The trade was a 17.31 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Erik Phelps sold 5,934 shares of the company’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $67.57, for a total transaction of $400,960.38. Following the completion of the sale, the executive vice president now directly owns 214,662 shares in the company, valued at $14,504,711.34. This trade represents a 2.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 2,229,449 shares of company stock valued at $102,293,124 in the last ninety days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TEM. First Horizon Advisors Inc. acquired a new stake in Tempus AI during the 3rd quarter worth about $30,000. Operose Advisors LLC acquired a new stake in Tempus AI during the fourth quarter worth about $25,000. Farther Finance Advisors LLC purchased a new position in Tempus AI during the fourth quarter valued at approximately $34,000. Prestige Wealth Management Group LLC raised its position in Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after acquiring an additional 965 shares in the last quarter. Finally, NewEdge Advisors LLC acquired a new position in Tempus AI in the fourth quarter valued at approximately $49,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.